Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Immunity. 2010 Apr 23;32(4):488-99. doi: 10.1016/j.immuni.2010.04.002.

Immunotherapy of type 1 diabetes: where are we and where should we be going?

Author information

  • 1Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA.

Abstract

Type 1 diabetes (T1D) is a chronic autoimmune disorder characterized by destruction of insulin-producing pancreatic beta cells. Many broad-based immunosuppressive and antigen-specific immunoregulatory therapies have been and are currently being evaluated for their utility in the prevention and treatment of T1D. Looking forward, this review discusses the potential therapeutic use of antigen-specific tolerance strategies, including tolerance induced by "tolerogenic" antigen-presenting cells pulsed with diabetogenic antigens and transfer of induced or expanded regulatory T cells, which have demonstrated efficacy in nonobese diabetic (NOD) mice. Depending on the time of therapeutic intervention in the T1D disease process, antigen-specific immunoregulatory strategies may be employed as monotherapies, or in combination with short-term tolerance-promoting immunoregulatory drugs and/or drugs promoting differentiation of insulin-producing beta cells from endogenous progenitors.

Copyright 2010 Elsevier Inc. All rights reserved.

PMID:
20412759
[PubMed - indexed for MEDLINE]
PMCID:
PMC2860878
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for PubMed Central
    Loading ...
    Write to the Help Desk